TD Cowen initiated coverage of Cartesian Therapeutics with a Buy rating. The company’s mRNA-based CAR-T approach for autoimmune allows for deep and durable responses, but with much cleaner safety and biologic-like administration, the analyst tells investors in a research note. The firm believes much share value will be created via Cartesian’s myasthenia gravis and other autoimmune diseases.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNAC:
- JMP Securities healthcare analysts hold an analyst/industry conference call
- Cartesian Therapeutics Announces New Employment Inducement Grants
- Cartesian Therapeutics price target raised to $43 from $38 at Canaccord
- Cartesian Therapeutics price target lowered to $49 from $54 at H.C. Wainwright
- Cartesian Therapeutics Strengthens Board of Directors with Appointment of Kemal Malik